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Genome-wide association study of
seasonal affective disorder
Kwo Wei David Ho1, Shizhong Han2, Jakob V. Nielsen3, Dubravka Jancic4, Benjamin Hing4, Jess Fiedorowicz4,
Myrna M. Weissman5,6, Douglas F. Levinson7 and James B. Potash 2
Abstract
Family and twin studies have shown a genetic component to seasonal affective disorder (SAD). A number of candidate
gene studies have examined the role of variations within biologically relevant genes in SAD susceptibility, but few
genome-wide association studies (GWAS) have been performed to date. The authors aimed to identify genetic risk
variants for SAD through GWAS. The authors performed a GWAS for SAD in 1380 cases and 2937 controls of European-
American (EA) origin, selected from samples for GWAS of major depressive disorder and of bipolar disorder. Further
bioinformatic analyses were conducted to examine additional genomic and biological evidence associated with the
top GWAS signals. No susceptibility loci for SAD were identiﬁed at a genome-wide signiﬁcant level. The strongest
association was at an intronic variant (rs139459337) within ZBTB20 (odds ratio (OR)= 1.63, p= 8.4 × 10−7), which
encodes a transcriptional repressor that has roles in neurogenesis and in adult brain. Expression quantitative trait loci
(eQTL) analysis showed that the risk allele “T” of rs139459337 is associated with reduced mRNA expression of ZBTB20 in
human temporal cortex (p= 0.028). Zbtb20 is required for normal murine circadian rhythm and for entrainment to a
shortened day. Of the 330 human orthologs of murine genes directly repressed by Zbtb20, there were 32 associated
with SAD in our sample (at p < 0.05), representing a signiﬁcant enrichment of ZBTB20 targets among our SAD genetic
association signals (fold= 1.93, p= 0.001). ZBTB20 is a candidate susceptibility gene for SAD, based on a convergence
of genetic, genomic, and biological evidence. Further studies are necessary to conﬁrm its role in SAD.
Introduction
Seasonal affective disorder (SAD) is a form of mood
disorder that typically occurs in late fall and winter when
periods of daylight are shortest. The hypothesis that light-
sensitivity is a core feature of this disorder is supported by
the efﬁcacy of bright light and dawn simulation therapies1.
Family and twin studies of SAD have suggested a genetic
component to its etiology. Studies of the relatives of SAD
probands have shown higher than expected rates of the
disorder in these family members, with rates in the range
of 14–26%2–4. A twin study demonstrated that genetic
effects account for at least 29% of the variance in sea-
sonality, including mood variation5.
Association studies using the candidate gene approach
have been applied to investigate the role of genetic var-
iation within biologically relevant genes in SAD suscept-
ibility. For example, variants in genes related to
serotonergic transmission, such as the serotonin trans-
porter gene SLC6A46 and the 5-HT2A receptor gene
HTR2A, have been associated with SAD at a suggestive
level of signiﬁcance7,8. Variants in the circadian genes
ARNTL, PER2, and NPAS2 have been reported to be
associated with SAD9,10. A variant in the melanopsin
gene, OPN4, which encodes a retinal protein essential for
registering light intensity, was nominally associated with
SAD in one report11.
Genome-wide association studies (GWAS) have been
widely used for identifying common variants associated
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with complex diseases. In contrast to the candidate gene
approach, GWAS allows for testing genetic variants
across the genome without reliance on prior knowledge
about disease biology. Genetic ﬁndings from GWAS are
shedding new light on psychiatric disorders, such as
depression, schizophrenia, and bipolar disorder12–14.
However, GWAS of SAD has to date been limited to one
study, which did not report any promising candidate
genes15.
In the current study, we performed a meta-analysis of
GWAS for SAD in 1380 cases and 2937 controls of
European-American (EA) origin, selected from samples
for GWAS of major depressive disorder (MDD) and of
bipolar disorder (BD). We report that ZBTB20 is a can-
didate susceptibility gene for SAD, based on a con-
vergence of genetic, genomic, and biological evidence.
Methods
Study samples
Case-control samples for SAD GWAS were selected
from those originally ascertained and assessed for MDD
or BD. Informed consent for participation in genetic
studies was obtained from all subjects. Basic information
for the study samples from each GWAS is summarized in
Table 1. The following provides details on the samples
included.
BD subjects were selected from the National Institute of
Mental Health (NIMH) Bipolar Genetics Study (BiGS).
The genotyping focused on European ancestry subjects
with Bipolar I (BPI) disorder from among those collected
by the NIMH Genetics Initiative for Bipolar Disorder in
ﬁve waves at 11 sites across the United States, as described
elsewhere in detail16. Only BPI cases were included in this
analysis. All cases were interviewed with the Diagnostic
Interview for Genetic Studies (DIGS), and these together
with interviewer observations, medical records and family
history data collected through the Family Interview for
Genetic Study (FIGS), were used to assign diagnoses
based on DSM-III or DSM-IV criteria following a best-
estimate procedure. Details of the DIGS and FIGS are
available at http://www.nimhgenetics.org.
MDD subjects were selected from the Genetics of
Recurrent Early-Onset Depression (GenRED) study.
GenRED I collected affected sibling pair families for
linkage studies, while GenRED II recruited cases for
association studies. Probands had MDD diagnosed with
either >1 episode or a single episode lasting >3 years,
onset before age 31, and a parent or a sibling with MDD
and age of onset <41. Proband information was gathered
through the DIGS, which together with an interviewer
narrative summary, available medical records and family
history data gathered through FIGS, was used to establish
a diagnosis based on DSM-IV criteria. Ascertainment and
assessment details for GenRED have been previously
described17.
Healthy control samples were obtained from the NIMH
Genetics Initiative repository. Some of these were selected
from among those ascertained through an NIMH-
supported contract mechanism between Dr. Pablo Gej-
man and Knowledge Networks, Inc.18. They were ascer-
tained to be free of psychiatric illness based on self-report
using the Composite International Diagnostic Interview—
Short Form, which assesses major depression, various
anxiety disorders, and alcohol and drug dependence. This
was augmented with three items inquiring about lifetime
diagnosis of, or treatment for, schizophrenia, schi-
zoaffective disorder, and bipolar disorder. A total of 1515
of these healthy control European ancestry (EA) subjects
were included for the BD GWAS. Another independent
set of 1422 healthy EA controls were included for the
MDD GWAS, which included 492 from the above data
set, and 930 more from the Genomic Psychiatry Cohort or
the Mayo Clinic Biobank.
Phenotype assignment
The assignment of the seasonal or nonseasonal case
status was based on identifying all subjects with seasonal
depressive episodes among BD or MDD patients. We used
a broad deﬁnition of seasonal depression. The assignment
of seasonal depression status was based on the subject’s
answer to “Do your depressions tend to begin in any
particular season?” question in DIGS. All subjects with
winter or fall answers were assigned seasonal case status
in our study, and all of the others with answers became
nonseasonal case subjects (non-SAD).
GWAS and quality control
All BD GWAS samples were genotyped with the Affy-
metrix 6.0 genome-wide SNP array at the Broad Institute
Center for Genotyping and Analysis. Different genotyping
efforts led to a partition of BiGS data into two sets: those
genotyped as a part of Genetic Association Information
Network Bipolar Sample (GAIN) and those genotyped as
Table 1 Basic information for the study samples from
each GWAS
Samples Platform SAD Non-SAD Controls
GAIN Affymetrix 6.0 296 427 1034
TGEN Affymetrix 6.0 436 665 401
TGEN2 Affymetrix 6.0 86 147 80
GENRED Affymetrix 6.0 325 671 492
GENRED2 Illumina Omni1-Quad 237 554 930
Total — 1380 2464 2937
SAD seasonal affective disorder, non-SAD nonseasonal affective disorder
Ho et al. Translational Psychiatry  (2018) 8:190 Page 2 of 8
a part of the Translational Genomic Research Institute
Sample (TGEN). The GAIN set includes subjects from the
ﬁrst four waves of the NIMH study, and a small subset of
wave ﬁve subjects. The TGEN set includes most of the
wave ﬁve subjects. GenRED samples were genotyped in
two waves. First wave samples were genotyped using the
Affymetrix 6.0 genome-wide SNP array, and the second
wave used the Illumina Omni1-Quad microarray
(GenRED2).
Initial quality control (QC) for each GWAS data set
removed subjects that failed set thresholds for call rates or
heterozygosity. We carried out additional QC ﬁltering for
each data set with the following criteria: minor allele
frequency (MAF) > 1%, missing rate per SNP < 5%, and
Hardy−Weinberg equilibrium (HWE) p value > 10−6.
After QC, there were 692,411 (GAIN), 701,183 (TGEN),
701,402 (TGEN2), 646,301 (GENRED), and 719,050
(GENRED2) autosomal SNPs retained for imputation. To
investigate population stratiﬁcation, we computed prin-
cipal components (PC) for GWAS samples using
EIGENSOFT19 based on a subset of SNPs that were in low
linkage disequilibrium with one another (r2 < 0.2). We did
not detect any outlier subjects from the PC analysis,
which were deﬁned as subjects whose ancestry was at least
three standard deviations from the mean on one of the
two largest PCs.
Imputation
Following the best practice guidelines of IMPUTE220,
we imputed 1000 Genomes variants into each GWAS
sample. Prephasing was ﬁrst performed with SHAPEIT21
to infer haplotypes for samples based on autosomal SNPs
with MAF > 0.01. Imputation was carried out on pre-
phased haplotypes using IMPUTE2 against haplotype
reference data from the 1000 Genomes Phase 3. After
postimputation QC (SNP missing rate < 0.05, MAF > 0.01,
imputation quality score > 0.5, and HWE > 10−6), there
were 8,462,922 (GAIN), 8,458,360 (TGEN), 8,272,185
(TGEN2), 8,452,433 (GENRED), and 8,498,837
(GENRED2) autosomal variants, among which the
majority of variants were imputed, with an average pro-
portion of 92% across study samples. A common set of
8,153,767 SNPs were retained for meta-analysis.
Association analysis
We ﬁrst carried out association analysis for each auto-
somal SNP with SAD in each sample, and then performed
meta-analysis to combine association evidence across
samples. In association analysis, to account for the
uncertainty of imputed genotypes, expected allelic dosa-
ges were used in a logistic regression framework as
implemented by SNPTEST22. Sex and the ﬁrst three PCs
of population structure were included as covariates. We
carried out meta-analysis based on effect size and
standard error using METAL under a ﬁxed-effect
model23. We evaluated the possibility of population stra-
tiﬁcation or other systemic biases by using the quantile
−quantile (QQ) plots based on p values of SNPs. Regional
association plots were created using the online web tool
LocusZoom24.
We computed gene-based p values using SimpleM25 to
evaluate the association evidence at the gene level. Sim-
pleM takes the smallest p value of SNPs within a gene
while correcting for the effective number of independent
SNPs through Bonferroni correction. The effective num-
ber of independent tests was estimated from the corre-
lation matrix of SNPs using PC analysis, so that the
corresponding eigenvalues explain 99.5% of the variation
for the SNP data. We assigned a SNP to a gene if it was
located within the gene, based on hg19 refGene annota-
tion, or within 20 kb upstream or downstream of the gene,
to capture regulatory variants.
Expression QTL (eQTL) analysis
To determine whether the lead SNP from association
analysis has an effect on regulating gene expression in
speciﬁc brain regions, we queried the brain eQTL online
database (http://www.braineac.org/), which contains
eQTL information for ten human brain regions. Full
details on the database are available elsewhere26.
Enrichment analysis for ZBTB20 candidate target genes
We examined whether ZBTB20 candidate target genes
were enriched for genes associated with SAD. Speciﬁcally,
a two-sided Fisher’s exact test was used to determine
whether there was an overrepresentation of nominally
signiﬁcant genes (p ≤ 0.05) among ZBTB20 candidate
targets in comparison to the remaining genes. Candidate
target genes of ZBTB20 were derived from a previous
study, in which ChIP-Seq combined with microarray gene
expression analysis approaches were applied to identify
346 murine genes directly repressed by Zbtb20 during
hippocampal CA1 neurogenesis in vivo27. The 346 murine
genes were mapped to 342 human orthologous ZBTB20
candidate target genes, of which 330 were assigned a
gene-level p value for SAD.
Results
Association analysis
The Manhattan plot for the meta-analysis of GWAS for
SAD is illustrated in Figure S1. The QQ plot of p values
indicated minimal evidence of population stratiﬁcation or
other systematic bias (lambda= 1.0, Figure S2). Overall,
no single SNPs were identiﬁed at genome-wide sig-
niﬁcance (p < 5×10−8). There were 90 SNPs associated
with SAD at p < 1×10−5 (Table S1). The strongest asso-
ciation evidence was at an intronic variant (rs139459337)
within ZBTB20 (odds ratio (OR)= 1.63, p= 8.4×10−7),
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which encodes a transcriptional repressor that plays a key
role in neurogenesis. Figure 1 shows the regional asso-
ciation plot for variants within and around ZBTB20.
Table 2 provides details of the association analysis
results for the lead SNP rs139459337. The minor allele
“T” was associated with an increased risk for SAD in each
sample. We found no signiﬁcant association for
rs139459337 with non-SAD (p= 0.76, Table S1), sug-
gesting the top GWAS signal was speciﬁc to SAD. A
broader case-only GWAS comparing SAD to non-SAD
cases did not reveal compelling signals; however,
rs139459337 differed between SAD and non-SAD with
OR of 1.47, and p value of 5.9×10−5 (Table S1).
We also evaluated the genetic association evidence
at the gene level for the SAD vs. healthy control
comparison; however, no genes reached genome-wide
signiﬁcance (p < 2×10−6). The strongest gene-level
association evidence was, again, for ZBTB20 (p=
8.0×10−5, Table S2).
eQTL analysis
We queried a brain eQTL database and examined
whether the lead SNP rs139459337 regulates ZBTB20
mRNA expression levels in ten brain regions. In this
small sample, we observed that the risk allele “T” was
associated with lower ZBTB20 mRNA levels in nine of
the ten regions, a difference that was nominally sig-
niﬁcant in the temporal cortex (p= 0.028) (Figure S3).
The result does not survive correction for multiple
testing.
Fig. 1 Regional association plot of SNPs in and around the top candidate gene ZBTB20. SNPs are plotted with their −log10 (p value) on the y-
axis along with their physical position (NCBI build 36) on the x-axis. The SNPs are color coded according to their correlations (r2), with the most
signiﬁcant SNP rs139459337 shown in purple. The light blue line and right y-axis indicate the observed recombination rates in the HapMap CEU
samples
Table 2 Association between rs139459337 and SAD in each sample and meta-analysis
Samples Info Minor allele MAF (cases) MAF (controls) OR 95% CI p
GAIN 0.95 T 0.093 0.062 1.59 1.13–2.25 0.01
TGEN 0.94 T 0.087 0.055 1.94 1.26–2.99 0.0021
TGEN2 0.80 T 0.078 0.063 1.45 0.51–4.12 0.49
GENRED 0.93 T 0.077 0.052 1.55 0.99–2.43 0.053
GENRED2 0.96 T 0.089 0.069 1.55 1.05–2.28 0.03
Meta-analysis — T 0.086 0.062 1.63 1.34–1.98 8.4×10−7
Info imputation quality score from Impute2, MAF minor allele frequency, OR odds ratio, CI conﬁdence interval
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Enrichment of GWAS signals for ZBTB20 candidate target
genes
Because both SNP and gene-level association analyses
implicated ZBTB20 as our strongest ﬁnding, we tested
whether there was an enrichment of SAD GWAS asso-
ciation signals for genes that are candidate targets for the
ZBTB20 transcriptional repressor protein. Of the 330
human orthologues of murine genes directly repressed by
Zbtb20, we found that 32 were associated with SAD (p <
0.05), representing a signiﬁcant enrichment as compared
to chance expectation (fold enrichment= 1.93, p= 0.001).
When we examined the QQ plot of p values, we found an
obvious deviation from the uniform expected distribution
for p values of the ZBTB20 candidate target gene group,
but not for the remaining nontarget genes (Fig. 2). Table
S3 provides a list of ZBTB20 targets that showed nom-
inally signiﬁcant association with SAD (p < 0.05).
Candidate genes
A number of candidate genes of biological interest have
previously been tested for their association with SAD.
These include genes related to serotonergic transmission,
such as SLC6A46 and HTR2A7,8; circadian genes, such as
ARNTL, PER2 and NPAS2; and OPN4, which encodes the
photoreceptive opsin protein. Using the number of
common SNPs (MAF > 0.01) that appear in the CEU
samples of 1000 Genomes as a reference, we ﬁrst eval-
uated whether our two genotyping platforms (Affymetrix
6.0 and Illumina Omni1-Quad) provided adequate cov-
erage of SNPs in these candidate genes. Although the two
genotyping arrays contained only a limited proportion of
SNPs within each candidate gene (ranging from 4 to 19%),
imputation greatly improved the coverage of these SNPs
(89−97%, Table S4). In our current GWAS, none of these
genes yielded SNPs with association p values < 1×10−3.
The gene with the strongest association evidence was
NPAS2, which included the SNP rs113837129, associated
with SAD at p= 0.001. Gene-level analysis of NPAS2
produced a trend toward association (p= 0.09). Gene-
level analyses did not show any signiﬁcant association
evidence for other candidate genes (p > 0.3). Table S5
provides the SNP-level analysis results with nominal sig-
niﬁcance for these candidate genes.
Discussion
In the current study, we conducted a GWAS for SAD in
an EA sample. Although no genome-wide signiﬁcant
ﬁndings were identiﬁed, we report that ZBTB20 is a
strong candidate susceptibility gene for SAD based on a
convergence of genetic, genomic, and biological evidence.
In particular, the lead SNP rs139459337 within ZBTB20
showed modest eQTL evidence for regulating gene
expression in temporal cortex. In addition, ZBTB20 can-
didate targets were enriched for genes nominally asso-
ciated with SAD.
Intriguingly, prior research suggests there is substantial
biological plausibility for ZBTB20 as a candidate gene for
SAD. ZBTB20 is a zinc ﬁnger transcriptional repressor
protein that is particularly abundant in the hippo-
campus27. The murine Zbtb20 gene is essential for the
speciﬁcation of hippocampal CA1 ﬁeld identity28. Ectopic
expression of Zbtb20 proteins in transgenic mice causes
behavioral abnormalities suggestive of deﬁciency in visual
and spatial memory processing29. Most strikingly, a recent
study reported that loss of Zbtb20 in mice impairs cir-
cadian rhythms, particularly reducing activity in the early
evening period of those nocturnal animals30. The Zbtb20-
deﬁcient mice also had more difﬁculty than control mice
in entraining to a shortened day.
Haploinsufﬁciency of ZBTB20 has been reported to be
involved in the neurodevelopmental and neuropsychiatric
disorders seen in the 3q13.31 microdeletion syndrome31
and in Primrose syndrome32. Interestingly, our eQTL
analysis indicated, albeit at a suggestive level, that the risk
allele of rs139459337 decreases ZBTB20 expression in
temporal cortex, which is in accordance with the hap-
loinsufﬁciency mechanism of ZBTB20 in neuropsychiatric
disorders. The reduced gene expression level of the risk
allele also parallels a previous study, which reported that
hypermethylation in the ZBTB20 gene was associated
with MDD33.
Our analysis has shown signiﬁcant enrichment of SAD
association signals for candidate gene targets of ZBTB20.
This result implies that pathways regulated by ZBTB20
Fig. 2 Stratiﬁed quantile−quantile (QQ) plot for ZBTB20
candidate gene targets (red) and nontarget genes from SAD
GWAS (black). The gray shading indicates 95% conﬁdence interval
under the null hypothesis of no association
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might be important in the etiology of SAD. A number of
candidate gene targets of ZBTB20 are worth noting, as
they have been implicated in various psychiatric disorders
and behavioral phenotypes. These include NRXN134,
NRXN335, and SYN336. The neurexins are a family of cell
adhesion molecules that act predominantly at the pre-
synaptic terminal in neurons and play essential roles in
neurotransmission and differentiation of synapses.
NRXN1 and NRXN3 have both been strongly implicated
in autism, and NRXN1 has been associated with schizo-
phrenia37. There have also been several studies suggesting
a relationship of these genes to mood disorders. Deletions
in NRXN1 were associated with poorer response to anti-
depressant medications38. A SNP in NRXN3 was asso-
ciated, at a genome-wide signiﬁcant level, with symptom
improvement during citalopram/escitalopram treatment,
though this did not replicate in additional samples39. Both
NRXN1 and NRXN3 have altered expression levels in
postmortem brains of suicide completers40. Interestingly,
NRXN1 has also been suggested to play a role in circadian
rhythm. Diurnal rhythms in mNRXN1 transcription were
found in the superchiasmatic nucleus of mice41. SYN3 is a
member of the synapsin gene family encoding neuronal
phosphoproteins that associate with the cytoplasmic
surface of synaptic vesicles. The SYN3 protein has a role
in synaptogenesis and the modulation of neurotransmitter
release. SYN3 was implicated in a study that examined
DNA methylation differences in MZ twins selected based
on discordance in cortisol and MRI measures related to
anxiety42.
Our analysis of candidate genes yielded little evidence of
association with SAD, though it did turn up nominally
signiﬁcant association in NPAS2. Notably, like Zbtb20,
Npas2 plays a role in circadian rhythms. It is closely
related in primary amino acid sequence to Clock, a
transcription factor expressed in the suprachiasmatic
nucleus (SCN) that regulates circadian rhythm. Npas2 was
identiﬁed as an analog of Clock operating as a circadian
regulator in the mammalian forebrain43. Later, it was
shown that Npas2 can functionally substitute for Clock in
the SCN in mice to regulate circadian rhythmicity44. In
one study Npas2-deﬁcient mice showed a number of
subtle differences in circadian activity as compared to
wild-type mice. Under normal 12-h light/12-h dark cycles
followed by constant darkness conditions, Npas2 (+/–)
and Npas2 (–/–) mice displayed rhythmic locomotor
activity largely comparable to that of wild-type littermates.
The exception is that Npas2 (–/–) mice postponed or
skipped a prominent break present in wild-type mice
during the middle of the night45. By comparison, Zbtb20
(–/–) mice, when compared with the Zbtb20 (+/–) and
control mice, displayed a dramatic loss of early evening
activity along with signiﬁcantly limited durations in their
early morning activity30. In terms of rhythmic oscillation
of locomotor activity, it was decreased in Npas2 (–/–)
mice compared to the wild-type and (+/–) mice. On the
other hand, the intrinsic period was increased in Zbtb20
(–/–) mice compared to the control mice.
This study should be considered in light of several
limitations. First, our assessment of seasonality was ret-
rospective. However, given that we were asking about a
recurring pattern, rather than a one-time event, recall
should be reasonably robust. Retrospective assessment of
SAD has also been found to be reliable45. A second lim-
itation lies in our deﬁnition of seasonality. We did not use
assessment tools such as the Seasonal Pattern Assessment
Questionnaire (SPAQ) to quantify seasonality based on
the Global Seasonality Score (GSS)46,47. Therefore, we are
not able to examine seasonality as a continuous pheno-
type. Finally, our sample size was small for a GWAS study,
and thus our power to detect genome-wide signiﬁcant
associations was limited.
In conclusion, our study identiﬁes ZBTB20 as a candi-
date susceptibility gene for SAD. Further study in inde-
pendent samples with the appropriate phenotype data is
needed to conﬁrm this association.
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